Lille

• A First-In-Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination with Cemiplimab Works in Adult Participan … Pending
  2025-523399-22-00 7 Melanoma
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Pending
  2025-524297-42-00 5 CLTI defined as Rutherford category 4 or 5
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• Phase 1 trial of valemetostat and darolutamide in mCRPC Recruiting
  2025-522512-16-00 3 2026-04-23 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors … Recruiting
  2023-507485-10-00 9 2026-04-21 advanced breast cancer
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting
  2024-516476-15-00 9 2026-03-04 Advanced gastrointestinal stromal tumor (GIST)
• First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting
  2025-521886-28-00 1 2026-02-19 Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Cast
• LUSPARA - Luspatercept in patients affected with rare inherited anemias Recruiting
  2024-520200-26-00 4 2026-02-13 Inherited anemias
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 1 2025-11-26 KRAS Altered Advanced or Metastatic Solid Tumors
• An Early Phase Clinical Trial to Evaluate COM701 in Relapsed Platinum Sensitive Ovarian Cancer (PSOC) Recruiting
  2025-521125-33-00 9 2025-09-05 Ovarian Cancer
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 3 2025-08-08 Advanced pancreatic adenocarcinoma

Showing 49–72 of 686 trials